Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Minyoung Jang
Observed names:
M Jang,
M Y Jang,
M. Jang,
M.Y. Jang
Institution:
Celltrion (South Korea)
Observed institution:
Celltrion (South Korea)
ORCID:
0000-0001-5145-297X
Observed ORCID:
0000-0001-5145-297X
OpenAlex ID:
A5083303353
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
2022
·
Laurent Peyrin-Biroulet
, Perttu Arkkila
, et al.
·
BMC Gastroenterology
·
62
PDF
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
2020
·
Minyoung Jang
, Steven Simoens
, et al.
·
BioDrugs
·
28
PDF
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
2022
·
Hyun Kyeong Yoo
, Han Geul Byun
, et al.
·
BMC Health Services Research
·
17
PDF
Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
2022
·
Yoram Bouhnik
, Raja Atreya
, et al.
·
Inflammatory Bowel Diseases
·
9
Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom
2021
·
Han Geul Byun
, Minyoung Jang
, et al.
·
Applied Health Economics and Health Policy
·
9
Budget impact of introducing an omalizumab biosimilar in 23 European countries
2025
·
Minyoung Jang
, Jooyeop Lee
, et al.
·
Journal of Medical Economics
·
5
PDF
Ab1185 Budget Impact Analysis of Introducing Subcutaneous Infliximab Ct-p13 Sc From the Uk Payer Perspective
2020
·
M. Perry
, M. Jang
·
Annals of the Rheumatic Diseases
·
3
PDF
HPR41 Biosimilars: The Key to Lowering Access Barriers to Omalizumab Across Europe
2024
·
S Yi
, H Yoo
, et al.
·
Value in Health
·
1
Uncovering the full economic impact of biosimilars: a “would have spent” counterfactual analysis of five reference biologics (infliximab, adalimumab, bevacizumab, rituximab, and trastuzumab) in the United States and Europe, 2016–2025
2026
·
Seungjae Yi
, Minyoung Jang
, et al.
·
Journal of Medical Economics
PDF
EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab
2025
·
Seungjae Yi
, Minyoung Jang
, et al.
·
Value in Health
EE109 Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries
2025
·
Minyoung Jang
, Joo Yeop Lee
, et al.
·
Value in Health
Perceived benefits and cost savings of liquid formulation of intravenous infliximab: perspectives of seven European countries
2025
·
Kyoungwan Nam
, Taek Sang Kwon
, et al.
·
Expert Opinion on Biological Therapy
PDF
EE513 Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab
2025
·
Seungjae Yi
, Minyoung Jang
, et al.
·
Value in Health
EE427 Analyzing the Impact of the Inflation Reduction Act of 2022 on Biosimilars in the United States: A Simulation with Adalimumab
2023
·
H.K. Yoo
, M. Jang
, et al.
·
Value in Health
PDF
P893 Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia
2023
·
H K Yoo
, M Y Jang
, et al.
·
Journal of Crohn s and Colitis
PDF
P888 Evaluating patient access to infliximab subcutaneous in inflammatory bowel disease
2023
·
M Jang
, H Yoo
, et al.
·
Journal of Crohn s and Colitis
PDF
Pbi17 Budget Impact Analysis of Intravenous Biosimilar Rituximab and Trastuzumab Compared to Intravenous and Subcutaneous Originators in France, Germany, Italy, Spain, and the Uk
2019
·
M.Y. Jang
, H.S. Choi
, et al.
·
Value in Health
PDF
Show more works
View as search
Works count:
17
Citation count:
134
H-index:
5
I10-index:
3
Year
Topic
Type
